1. Home
  2. FATE vs CSBR Comparison

FATE vs CSBR Comparison

Compare FATE & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • CSBR
  • Stock Information
  • Founded
  • FATE 2007
  • CSBR 1985
  • Country
  • FATE United States
  • CSBR United States
  • Employees
  • FATE N/A
  • CSBR N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • CSBR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FATE Health Care
  • CSBR Health Care
  • Exchange
  • FATE Nasdaq
  • CSBR Nasdaq
  • Market Cap
  • FATE 142.4M
  • CSBR 151.0M
  • IPO Year
  • FATE 2013
  • CSBR 1986
  • Fundamental
  • Price
  • FATE $1.42
  • CSBR $10.17
  • Analyst Decision
  • FATE Hold
  • CSBR Strong Buy
  • Analyst Count
  • FATE 10
  • CSBR 1
  • Target Price
  • FATE $6.75
  • CSBR $8.00
  • AVG Volume (30 Days)
  • FATE 2.1M
  • CSBR 46.1K
  • Earning Date
  • FATE 03-04-2025
  • CSBR 03-11-2025
  • Dividend Yield
  • FATE N/A
  • CSBR N/A
  • EPS Growth
  • FATE N/A
  • CSBR N/A
  • EPS
  • FATE N/A
  • CSBR N/A
  • Revenue
  • FATE $13,447,000.00
  • CSBR $53,571,000.00
  • Revenue This Year
  • FATE N/A
  • CSBR $14.19
  • Revenue Next Year
  • FATE N/A
  • CSBR $10.11
  • P/E Ratio
  • FATE N/A
  • CSBR N/A
  • Revenue Growth
  • FATE N/A
  • CSBR 7.19
  • 52 Week Low
  • FATE $1.04
  • CSBR $3.60
  • 52 Week High
  • FATE $8.83
  • CSBR $11.99
  • Technical
  • Relative Strength Index (RSI)
  • FATE 48.76
  • CSBR 48.12
  • Support Level
  • FATE $1.43
  • CSBR $10.32
  • Resistance Level
  • FATE $1.81
  • CSBR $11.33
  • Average True Range (ATR)
  • FATE 0.14
  • CSBR 0.99
  • MACD
  • FATE 0.05
  • CSBR -0.20
  • Stochastic Oscillator
  • FATE 39.06
  • CSBR 29.57

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Share on Social Networks: